Memento Medicines launches with focus on ophthalmology

June 19, 2026

Memento Medicines Inc. has announced its launch with a $93 million series A financing and the licensing of a lead program for retinal diseases.

Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific

May 12, 2026

By Marian (YoonJee) Chu

No Comments

Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.

Ocular

Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific

May 12, 2026

By Marian (YoonJee) Chu

No Comments

Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific

May 11, 2026

By Marian (YoonJee) Chu

No Comments

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

BioWorld Science

Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...

Investors bet on transformative BCI tech for neuro disorders

BioWorld

An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....